GlaxoSmithKline: Dolutegravir (whose brand name will be Tivicay) approved by the FDA

NEUTRAL, Fair Value  1900p (+14%)

News published on August Tuesday 13, 2013
Share on

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities